Compare Mongodb Inc (MDB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Viatris Inc — how do they compare? Mongodb Inc trades at $374.06 (market cap $29.24B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Mongodb Inc is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 45 Days and Viatris Inc for 57 Days on average.
| MDB | VTRS | |
|---|---|---|
Market Cap | $29.24B | $20.03B |
Volume | 1,304,995 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $472.29 | $18.27 |
52-Week Low | $225.95 | $9.74 |
Typical Hold Time | 45 Days | 57 Days |
Enterprise Value | $26.86B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $363.03, up 0.64% today, amid a bearish technical signal despite recent earnings beats. The stock faces headwinds with a high P/E of 511.31 and negative net income, though revenue growth remains strong, reaching $2.01B in 2025. Recent news highlights AI product launches and a CEO transition, with investor sentiment mixed following a sharp sell-off.
Outlook: Long-term growth potential exists with raised AI-focused targets, but high valuation and profitability challenges pose risks. Analyst consensus is bullish with an $456.76 price target, yet technical indicators and cash flow volatility warrant caution for near-term volatility.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
